CSL Behring
CSL Behring is one of the world’s leading specialty biologics companies, focused on plasma-derived therapies, immunoglobulins, hemophilia, hereditary angioedema, immunology, and rare diseases. Its business model is highly specialized, combining biologic manufacturing, plasma collection, global distribution, and specialist medicine.
- Highest 2026 tier: Tier II
- Specialty Pharma Companies
- 1 ranking category
Overview
CSL Behring is one of the world’s leading specialty biologics companies, focused on plasma-derived therapies, immunoglobulins, hemophilia, hereditary angioedema, immunology, and rare diseases. Its business model is highly specialized, combining biologic manufacturing, plasma collection, global distribution, and specialist medicine.
The company’s strength lies in complex biologics infrastructure. Plasma-derived and recombinant specialty therapies require highly controlled manufacturing, supply-chain management, regulatory oversight, and patient-specific clinical use.
CSL Behring is included in 1 2026 ranking category. Its highest classification is Tier II. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | CSL Behring |
| Founded | 1916 |
| Institution type | Specialty Pharma Companies institution |
| Headquarters | King of Prussia, United States / Melbourne, Australia |
| Primary focus | Specialty Pharma Companies |
| Highest 2026 ranking tier | Tier II |
Principal activities
The company’s strength lies in complex biologics infrastructure. Plasma-derived and recombinant specialty therapies require highly controlled manufacturing, supply-chain management, regulatory oversight, and patient-specific clinical use.
Core capability
Specialty Pharma Companies
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Specialty Pharma Companies
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
CSL Behring’s products serve patients with serious and often rare conditions requiring long-term therapy. Its role in immunoglobulin therapy, coagulation disorders, and specialty biologics gives it strong relevance within the specialty pharma ecosystem.
CSL Behring is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier II.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. CSL Behring should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as CSL Behring. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | CSL Behring |
| Headquarters | King of Prussia, United States / Melbourne, Australia |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Specialty Pharma Companies 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
